{
    "guideline_identifier": "PIIS0923753421044987.txt",
    "cancer_focus": {
        "primary_cancer": "Metastatic Breast Cancer",
        "related_syndrome_or_condition": "Hereditary Breast and Ovarian Cancer Syndrome, Oligometastatic Disease, Leptomeningeal Metastases, CNS Metastases"
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Metastatic (Stage IV)",
            "risk_group": "HR+/HER2-",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "CDK4/6 inhibitor (ribociclib, palbociclib, abemaciclib) + endocrine therapy (AI or fulvestrant)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "ER",
                            "status": "Positive",
                            "testing_guidance": "Mandatory at metastatic biopsy"
                        },
                        {
                            "name": "PR",
                            "status": "Positive or Negative",
                            "testing_guidance": "Mandatory at metastatic biopsy"
                        },
                        {
                            "name": "HER2",
                            "status": "Negative",
                            "testing_guidance": "Mandatory at metastatic biopsy"
                        }
                    ],
                    "esmo_evidence_level": "Level I A"
                },
                {
                    "clinical_context": "Second-line with PIK3CA mutation",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Alpelisib + fulvestrant",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "PIK3CA",
                            "status": "Mutated",
                            "testing_guidance": "Tissue/ctDNA testing post-CDK4/6 progression"
                        }
                    ],
                    "esmo_evidence_level": "Level I B"
                },
                {
                    "clinical_context": "Second-line with gBRCAm",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "PARP inhibitor (olaparib/talazoparib)",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "gBRCA",
                            "status": "Mutated",
                            "testing_guidance": "Germline testing"
                        }
                    ],
                    "esmo_evidence_level": "Level I A"
                },
                {
                    "clinical_context": "Post-CDK4/6 progression without mutations",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Everolimus + exemestane",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I B"
                }
            ]
        },
        {
            "staging_criteria": "Metastatic (Stage IV)",
            "risk_group": "HER2+",
            "treatment_plans": [
                {
                    "clinical_context": "First-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pertuzumab + trastuzumab + taxane → maintenance pertuzumab/trastuzumab",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "HER2",
                            "status": "Positive",
                            "testing_guidance": "Mandatory IHC/FISH at diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level I A"
                },
                {
                    "clinical_context": "Second-line therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Trastuzumab deruxtecan (preferred) or T-DM1",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I A"
                },
                {
                    "clinical_context": "With CNS metastases",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Tucatinib + trastuzumab + capecitabine",
                    "treatment_line": "Any line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level II A"
                }
            ]
        },
        {
            "staging_criteria": "Metastatic (Stage IV)",
            "risk_group": "TNBC",
            "treatment_plans": [
                {
                    "clinical_context": "First-line PD-L1+ (CPS≥10)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pembrolizumab + chemotherapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "PD-L1",
                            "status": "Positive (CPS≥10)",
                            "testing_guidance": "IHC testing prior to 1st-line"
                        }
                    ],
                    "esmo_evidence_level": "Level I A"
                },
                {
                    "clinical_context": "First-line gBRCAm",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "PARP inhibitor (olaparib/talazoparib) or platinum-based chemo",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "gBRCA",
                            "status": "Mutated",
                            "testing_guidance": "Germline testing"
                        }
                    ],
                    "esmo_evidence_level": "Level I A"
                },
                {
                    "clinical_context": "Post-anthracycline/taxane",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Sacituzumab govitecan",
                    "treatment_line": "Later-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I A"
                }
            ]
        },
        {
            "staging_criteria": "Metastatic (Stage IV)",
            "risk_group": "Oligometastatic Disease",
            "treatment_plans": [
                {
                    "clinical_context": "Limited metastatic sites",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Multimodal therapy (surgery/radiotherapy + systemic therapy)",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level II C"
                }
            ]
        },
        {
            "staging_criteria": "Metastatic (Stage IV)",
            "risk_group": "Bone Metastases",
            "treatment_plans": [
                {
                    "clinical_context": "Skeletal involvement",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Bone-modifying agents (zoledronate/denosumab) + radiotherapy for pain/fracture risk",
                    "treatment_line": "",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I A"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "ER/PR/HER2 for therapy selection; PIK3CA mutations predict alpelisib response; gBRCA mutations predict PARP inhibitor efficacy; PD-L1 status predicts immunotherapy benefit in TNBC; ESCAT Tier I-A biomarkers (gBRCAm, PIK3CAm, PD-L1+) have highest clinical actionability"
    }
}